Iort denied as not FDA-approved for this use by Aetna?

Aetna considers IORT medically necessary for select early-stage breast cancer patients meeting TARGIT-A inclusion criteria: age ≥50, unifocal invasive ductal carcinoma, T1 (≤2cm), node-negative, hormone-receptor positive, HER2-negative, no extensive intraductal component. IORT may be delivered as single-fraction at lumpectomy (boost) or as primary partial-breast irradiation. Aetna considers IORT investigational/experimental for most non-breast indications (rectal, glioblastoma, sarcoma, recurrent rectal/pelvic) absent specific guideline support.

TARGIT-A 5-yr long-term (Vaidya BMJ 2020;370:m2836) — non-inferior local control vs WBRT for selected patients meeting TARGIT-A criteria, sustained at 12-yr follow-up (Vaidya 2024). ELIOT 5-yr + 10-yr (Veronesi Lancet Oncol 2013;14:1269; Orecchia 2021) — Italian electron IORT outcomes for selected low-risk profile. GEC-ESTRO consensus on partial-breast irradiation 2010/2024 update (Strnad). ASTRO APBI Consensus Statement 2017/update — IORT category eligibility table. NCCN Breast Cancer v2.2024 lists IORT as APBI option meeting selection criteria. For rectal IORT cite NCCN Rectal Cancer v3.2024 (locally advanced + R0 close margin) and Calvo et al EJC 2014 IORT outcomes. Document staging completion (sentinel node, IHC), final pathology with margins, multidisciplinary tumor board recommendation. Submit ABS / ASTRO / ASCO position statements where applicable.

## Why Aetna Denies Intraoperative Radiation Therapy as Not FDA-Approved — and How to Appeal

A not-FDA-approved denial for Intraoperative Radiation Therapy (IORT) is often a misclassification. The IORT devices used in clinical practice — such as mobile linear accelerators and electronic brachytherapy applicators — have received FDA 510(k) clearance or premarket approval for their indicated uses. If Aetna has characterized IORT as not FDA-approved, the appeal must first establish the precise regulatory status of the device and technique being used, because the factual premise of the denial may be incorrect.

## Why This Denial Is Appealable

FDA device clearance or approval is distinct from payer coverage policy. If the IORT device used at your treating facility has received FDA clearance for the specific indication, the not-FDA-approved denial can be factually refuted by producing the device's FDA clearance documentation. Even where a payer argues that FDA clearance is insufficient — because the device is being used in a specific clinical scenario not expressly addressed in the clearance — the treating oncologist can argue that use within the cleared indication is appropriate and supported by professional society guidelines.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or applicable state law within the deadline on the denial notice. In the appeal, directly challenge the factual basis of the denial by submitting FDA clearance documentation for the IORT device used.
• External review: If the internal appeal is denied, escalate under ACA §2719 to an independent IRO within four months of the final adverse determination. External reviewers apply clinical and regulatory standards independently of Aetna's internal policy.
• Expedited review: If surgery is scheduled and delay would compromise care, request expedited review — decisions are typically required within 72 hours.

## Documentation to Gather

• FDA clearance documentation: The 510(k) clearance summary or PMA approval letter for the specific IORT device used at the treating facility. The facility's medical physics or radiation oncology department can provide this.
• Device-specific indication: Confirmation from the facility that the device is being used within its FDA-cleared indication for the patient's specific cancer type and clinical scenario.
• Treating oncologist's letter: A letter from the radiation oncologist explaining the regulatory status of IORT, the device used, its FDA clearance, and the clinical rationale for its use in this case.
• Professional society guidance: Reference to the applicable ASTRO, NCCN, or SSO guideline supporting IORT in this clinical scenario, reinforcing that the treatment is accepted clinical practice.
• Diagnosis and staging: Complete pathology and staging documentation relevant to the IORT indication.

## Criteria-Mapping Structure

Obtain the denial letter's exact language regarding FDA approval. Identify whether the denial refers to the device, the technique, or the indication. Respond point-by-point: cite the device's FDA clearance number and cleared indication, confirm that the clinical use falls within that clearance, and cite supporting oncology guidelines. If the denial is based on a misunderstanding of the FDA clearance framework for radiation devices, say so explicitly and respectfully — and ask Aetna to reconsider based on the corrected regulatory record.